This needs to be shared again as we are all sitting on a monster...

This needs to be shared again as we are all sitting on a monster in the making (and the previous link didn't work)
Key highlights:
-Infectious disease company in the middle of an infectious disease crisis.
-Low shares on issue with very few options avail.
-To 31% plus of company owned by board
-Big R&D rebate incoming
-Outstanding board (go look up credentials)
-Phase 1 in human study data could even potentially read out late 2nd half 2020!
-Topical burns study in WA with very senior burns expert, awaiting human ethics approval which is expected anytime now
- US 529 study for coronavirus, imminent data readout by end Sept. Same with CSRIO/Doherty in Aus
(US REGULATORY PATHWAY - COULD JUMP VERY PROMPTLY INTO HUMAN TRIALS DUE TO COVID!)
-Excellent patent family coverage
- Recce 435 better than best in class for H.Pylori
-Water soluble at all PH levels
-Could be administered as a preventative (think surgery at hospital) as no bacterial resistance
-1 in 3 die of sepsis due to lead times (pathology), as Recce is broad spectrum it can be administered straight away...
IF RECCE COMPOUNDS WORK IN HUMANS AS THEY HAVE IN THE LAB AND TEST ANIMALS WE WILL BE CHANGING MEDICINE FOREVER! THE MARKET IS ENORMOUS!
Video below